within Pharmacolibrary.Drugs.ATC.C;

model C02KX54
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600,            
    Vdp             = 0.03,
    k12             = 8,
    k21             = 8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KX54</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Macitentan and tadalafil is a fixed-dose combination medication indicated for the treatment of pulmonary arterial hypertension (PAH) to reduce morbidity. Macitentan is an endothelin receptor antagonist, and tadalafil is a phosphodiesterase type 5 inhibitor. This combination is approved in several regions for PAH management.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic estimates for healthy adults. No published pharmacokinetic models with joint parameter estimates for the fixed-dose combination are currently available; parameters are estimated based on models for separate agents.</p><h4>References</h4><ol><li><p>Ford, JL, et al., &amp; Csonka, D (2024). Bioequivalence and the food effect of macitentan/tadalafil 10/20 fixed-dose combination tablets versus the use of single-component tablets in healthy subjects. <i>Pharmacology research &amp; perspectives</i> 12(3) e1202–None. DOI:<a href=&quot;https://doi.org/10.1002/prp2.1202&quot;>10.1002/prp2.1202</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38764241/&quot;>https://pubmed.ncbi.nlm.nih.gov/38764241</a></p></li><li><p>Tanaka, S, et al., &amp; Namiki, N (2020). Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. <i>Die Pharmazie</i> 75(6) 236–239. DOI:<a href=&quot;https://doi.org/10.1691/ph.2020.0021&quot;>10.1691/ph.2020.0021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32539916/&quot;>https://pubmed.ncbi.nlm.nih.gov/32539916</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KX54;
